Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into
mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies …

Objective This guideline will provide the practicing endocrinologist with an approach to the
assessment and treatment of dyslipidemia in patients with endocrine diseases, with the …

Objective The development of these guidelines is mandated by the American Association of
Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology …

Importance Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were recently
approved for lowering low-density lipoprotein cholesterol in heterozygous familial …

An increased risk of cardiovascular disease, independent of conventional risk factors, is
present even at minor levels of renal impairment and is highest in patients with end-stage …

Background Despite the availability of effective drug therapies that reduce low‐density
lipoprotein (LDL)‐cholesterol (LDL‐C), cardiovascular disease (CVD) remains an important …

Ever since loss of survival motor neuron (SMN) protein was identified as the direct cause of
the childhood inherited neurodegenerative disorder spinal muscular atrophy, significant …

Background We sought to examine the efficacy and safety of 2 PCSK9 (proprotein
convertase subtilisin/kexin type 9) inhibitors: alirocumab and evolocumab. Methods and …

Purpose Even with statins and other lipid-lowering therapy (LLT), many patients with
heterozygous familial hypercholesterolemia (heFH) continue to have elevated low-density …

Coronary artery disease (CAD) is one of the most common causes of death worldwide. In the
last decade, significant advancements in CAD treatment have been made. The existing …